Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 10, 2008. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,500,000 Ordinary shares of 25 pence each.
- Purchase Date: December 10, 2008.
- Purchase Price: 1,205.24 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.13% of total voting rights).
- Shares in Issue: 5,193,098,653 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the cancellation of the 1,500,000 shares purchased on December 10, 2008. This transaction increased the proportion of Treasury shares held by the Company to 9.13% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard disclaimer stating the announcement does not constitute an offer or solicitation to purchase securities and confirms conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,193,098,653) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on total voting rights (9.13%).
- Note that this filing does not contain operational or financial performance data for the period.